Samuel Jaimez Alvarado

Dr. Samuel Jaimez Alvarado

Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Samuel Jaimez AlvaradoSamuel Jaimez Alvarado
Samuel Jaimez Alvarado
ILItzel Ivonn López
Itzel Ivonn López
JSJavier Barragán-De Los Santos
Javier Barragán-De Los Santos
DBDannya Coral Bello-Vega
Dannya Coral Bello-Vega
FRANCISCO-JAVIER ROLDANFRANCISCO-JAVIER ROLDAN
FRANCISCO-JAVIER ROLDAN
MAMaria Magdalena Aguirre-Garcia
Maria Magdalena Aguirre-Garcia
An intriguing aspect of restrictive cardiomyopathies (RCM) is the microbiome role in the natural history of the disease. These cardiomyopathies are often difficult to diagnose and so result in significant morbidity and mortality. The human microbiome, composed of billions of microorganisms, influences various physiological and pathological processes, including cardiovascular health. Studies have shown that gut dysbiosis, an imbalance in the composition of intestinal bacteria, can contribute to systemic inflammation, a key factor in many cardiovascular conditions. An increase in gut permeability, frequently caused by dysbiosis, allows bacterial endotoxins to enter the bloodstream, activating inflammatory pathways that exacerbate cardiac dysfunction. Recent reports highlight the potential role of microbiome in amyloidogenesis, as certain bacteria produce proteins that accelerate the formation of amyloid fibrils. Concurrently, advancements in amyloidosis treatments have sparked renewed hopes, marking a promising era for managing these kinds of diseases. These findings suggest that the gut–heart axis may be a potential factor in the development and progression of cardiovascular disease like RCM, opening new paths for therapeutic intervention. The aim of this review is to provide a detailed overview of the gut–heart axis, focusing on RCM.

Verified
Journal Article
Open access
PDF file
ILItzel Ivonn López
Itzel Ivonn López
LCLuis Alejandro Constantino-Jonapa
Luis Alejandro Constantino-Jonapa
Samuel Jaimez AlvaradoSamuel Jaimez Alvarado
Samuel Jaimez Alvarado
FHFernando Hernández-Quiroz
Fernando Hernández-Quiroz
EJEsteban Jorge-Galarza
Esteban Jorge-Galarza
MAMaria Magdalena Aguirre-Garcia
Maria Magdalena Aguirre-Garcia
Cardiac amyloidosis is a rare and progressive condition characterized by the extracellular deposition of amyloid fibrils in multiple organs. Wild-type transthyretin amyloidosis (ATTR-wt) is the most common type affecting subjects above 60 years old. Recent and growing evidence suggests a potential link between GM and cardiac amyloidosis. In this scenario, the aim of the present study is to characterize the gut microbiota (GM), related metabolites and inflammatory biomarkers in ATTR-wt patients. In the ATTR patients we identified Prevotella_9 as the core OTUs (Operational Taxonomic Unit) of this group, alongside Prevotella 7, Prevotellaceae_UCG-003 and Prevotellaceae_NK3B31. In addition, there were increased levels of long fatty acids, including tetradecanoic, hexadecanoic and octadecanoic acids, in the ATTR group. The data obtained suggest that ATTR patients have an altered gut microbiota that could be used as a potential biomarker in metabolic and cardiovascular diseases, as well as a potential predictor of adverse prognosis in ATTR patients. In addition, the intestinal dysbiosis in ATTR patients could be associated with low-grade endotoxemia promoting a pro-inflammatory state due to the translocation of bacterial components, such as LPS (lipopolysaccharide), into blood circulation.